| 561 | In combination with dexamethasone for once per-cycle treatment in adult patients for:
- Prevention of acute and delayed nausea and vomting associated with highly emetogenic cancer chemotherapy (HEC).
Highly emetogenic chemotherapy (HEC) regimens:
- Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70mg per meter squared
- Cisplatin and cyclophosphamide combinations where the single daily dose of cisplatin is greater than or equal to 50mg per meter squared
- Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide).
Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each HEC. |
| | LU Authorization Period: 1 year |
| 562 | In combination with dexamethasone for once per-cycle treatment in adult patients for:
- Prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy (MEC) that is uncontrolled by a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist (RA) alone in a previous cycle.
Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each MEC cycle. |
| | LU Authorization Period: 1 year |
